HealthTech: $33M to research anesthesia drugs | Medical device innovation center | Sexton Biotechnologies
- ST. LOUIS, MO—Intravenous propofol and inhaled anesthetic drugs are the two most common general anesthesia drugs for surgical patients in the U.S. Researchers at the Washington University School of Medicine in St. Louis and the University of Michigan have gotten $33 million to compare the two drugs to determine which offers better patient recovery experiences and improved clinical outcomes.
- INDIANAPOLIS, IN—BioLife Solutions, Inc. entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton Biotechnologies, Inc., which provides products and services to those creating cell and gene therapies. The proposed acquisition will enable BioLife Solutions to expand its cell and gene therapy tools portfolio.
- PITTSBURGH, PA—A collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh School of Medicine and New Jersey-based biotechnology company Avalon GloboCare Corp. aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring treatments to cancer patients within days instead of weeks.
- ST. PAUL, MN—Ecolab, which develops and offers services, technology and systems that specialize in water treatment, purification, cleaning and hygiene, is opening a state-of-the-art innovation center. The 22,000-square-foot advanced design center will help Ecolab partner with medical device industry customers on infection prevention and help develop new solutions for hospitals and surgery centers.